JW Pharmaceutical Corporation (KRX:001060)
South Korea
· Delayed Price · Currency is KRW | Market Cap | 741.75B |
| Revenue (ttm) | 775.30B |
| Net Income (ttm) | 61.51B |
| Shares Out | 22.89M |
| EPS (ttm) | 2,534.00 |
| PE Ratio | 12.83 |
| Forward PE | n/a |
| Dividend | 450.00 (1.40%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | 26,902 |
| Average Volume | 74,738 |
| Open | 32,800 |
| Previous Close | 32,500 |
| Day's Range | 31,950 - 32,850 |
| 52-Week Range | 20,700 - 39,250 |
| Beta | 1.18 |
| RSI | 57.36 |
| Earnings Date | May 14, 2026 |
About JW Pharmaceutical
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam sterilizer, and other equipment. In addition, it offers wound care, pain care, and beauty care related products. The company was founded in 1945 and is base... [Read more]
Financial Performance
In 2025, JW Pharmaceutical's revenue was 775.30 billion, an increase of 7.77% compared to the previous year's 719.38 billion. Earnings were 61.51 billion, a decrease of -5.43%.
Financial StatementsNews
Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
BEIJING and BRIDGEWATER, N.J. , April 9, 2026 /CNW/ -- Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW...